Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, reposted from Thalassaemia International Federation (TIF) on LinkedIn:
”Very impressed with all the tech and regulatory advances deployed by the Ministry of Health Saudi Arabia and the leadership of Dr Hatoon Ezzat dedicated to the management of inherited blood disorders in general and thalassemia in specific. Outcomes from such initiatives will surely have global implications on disease understanding and care.”
Quoting Thalassaemia International Federation (TIF)‘s post:
”High-Level TIF–Kingdom of Saudi Arabia Strategic Meeting | 14 December 2025
A high-level delegation of the Thalassaemia International Federation – TIF held a strategic meeting on 14 December 2025 with senior representatives of the Ministry of Health Saudi Arabia, underscoring a shared commitment to accelerating progress in the prevention, control, and comprehensive management of thalassaemia and other haemoglobinopathies.
The TIF delegation comprised Dr. Androulla Eleftheriou, TIF Executive Director; Prof. john porter, Professor of Haematology and Consultant Haematologist at University College London Hospitals (UK); Prof. Khaled Musallam, MD, PhD, Group Chief Research Officer of Burjeel Holdings and Founding Director of CR-RBD (UAE); and Prof. Dimitrios Farmakis, MD, PhD, FESC, FHFA, Professor of Cardiology at the National and Kapodistrian University of Athens (Greece), members of TIF’s International Scientific Advisory Board.
The delegates met with H.E. Dr. Mohammed K. Alabdulaali, Assistant Deputy Minister for Hospital Services; Dr. Hatoon Ezzat, Assistant Minister’s Advisor and General Supervisor of Blood Disorders; and Prof. Ahmad Tarawah, Consultant in Pediatric Hematology/Oncology.
During the discussions, TIF congratulated the Government of the KSA on its notable progress in strengthening national systems for the control and management of thalassaemia and other haemoglobinopathies, as well as on the impressive outcomes of its health-sector digitaltransformation.
Particular emphasis was placed on advancing integrated digital health ecosystems and strengthening datasystems, enabling smarter service planning, better follow-up, improved continuity of care, and a more streamlined patientjourney across different levels of the health system.
TIF also commended the KSA’s leadership in facilitating access to healthinnovation, including its distinction as the first country globally to authorise the novel oral therapy PYRUKYND® (mitapivat) for adult patients with transfusion-dependent (TDT) and non-transfusion-dependent (NTDT) α- or β-thalassaemia.
Building on an already excellent and long-standing collaboration between TIF and the KSA, the meeting also explored a forward-looking agenda of joint initiatives.
These include co-developed educational activities and collaborative actions that could support regional and international efforts to improve standards of care and outcomes for patients and their families.”
Stay updated with Hemostasis Today.
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs
-
Mar 18, 2026, 16:07Scott Isaacs: Optimizing Brain Vitality and Slowing Neurodegeneration Through Daily Habits